Inventiva (IVA) announced a leadership transition with the appointment of Jason Campagna as president of research and development and CMO. Campagna is joining Inventiva’s executive leadership team and brings extensive expertise in the MASH field. He succeeds Pierre Broqua, co-founder and chief scientific officer, who is transitioning to a consulting role and Michael Cooreman departing as CMO of the company. Campagna most recently was the CMO at Q32 Bio.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVA:
- Inventiva Secures $10 Million Milestone from CTTQ for MASH Therapy Development
- Inventiva receives $10M milestone payment from Chia Tai-Tianqing Pharmaceutical
- 3 Best Stocks to Buy Now, 6/6/2025, According to Top Analysts
- Inventiva’s Lanifibranor: A Promising Investment in the MASH Space with Strong Phase III Progress and Financial Backing
- Inventiva Reports Q1 2025 Financials and Strategic Developments